11月19日，康缘药业盘中下跌2.06%，截至13:18，报15.20元/股，成交8470.28万元，换手率0.97%，总 市值86.06亿元。 资金流向方面，主力资金净流出643.92万元，大单买入1109.59万元，占比13.10%，卖出1753.51万元， 占比20.70%。 截至9月30日，康缘药业股东户数4.05万，较上期增加17.20%；人均流通股13969股，较上期减少 14.68%。2025年1月-9月，康缘药业实现营业收入23.43亿元，同比减少24.66%；归母净利润2.00亿元， 同比减少44.10%。 责任编辑：小浪快报 资料显示，江苏康缘药业股份有限公司位于江苏省连云港市经济技术开发区江宁工业城，成立日期1996 年5月8日，上市日期2002年9月18日，公司主营业务涉及涉及药品的研发、生产与销售。主营业务收入 构成为：口服类58.68%，注射类33.28%，外用类8.04%。 康缘药业所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：中药、禽流感药物、医药电 商、抗流感、小盘等。 分红方面，康缘药业A股上市后累计派现9.48亿元。近三年，累计派现3.45亿元。 机构持仓方 ...

截至9月30日，万孚生物股东户数4.24万，较上期减少5.59%；人均流通股10160股，较上期增加5.94%。 2025年1月-9月，万孚生物实现营业收入16.90亿元，同比减少22.52%；归母净利润1.34亿元，同比减少 69.32%。 分红方面，万孚生物A股上市后累计派现12.13亿元。近三年，累计派现6.01亿元。 资料显示，广州万孚生物技术股份有限公司位于广东省广州市黄埔区科学城荔枝山路8号，成立日期 1992年11月13日，上市日期2015年6月30日，公司主营业务涉及快速诊断试剂、快速检测仪器等POCT 相关产品的研发、生产与销售。主营业务收入构成为：慢性疾病检测45.93%，传染病检测30.93%，毒 品(药物滥用)检测11.82%，妊娠及优生优育检测11.27%，其他(补充)0.04%。 万孚生物所属申万行业为：医药生物-医疗器械-体外诊断。所属概念板块包括：基因测序、抗流感、幽 门螺杆概念、互联医疗、肝炎治疗等。 11月19日，万孚生物盘中下跌2.08%，截至13:00，报21.23元/股，成交6821.89万元，换手率0.74%，总 市值99.37亿元。 资金流向方面，主力资金净流出1 ...

Core Viewpoint - Yisheng Pharmaceutical's stock has experienced fluctuations, with a year-to-date increase of 23.66% but a recent decline of 2.12% over the past five trading days [1][2]. Financial Performance - For the period from January to September 2025, Yisheng Pharmaceutical reported a revenue of 476 million yuan, representing a year-on-year decrease of 5.81%. The net profit attributable to shareholders was 24.13 million yuan, down 32.72% compared to the previous year [2]. - Cumulative cash dividends since the company's A-share listing amount to 213 million yuan, with 99.29 million yuan distributed over the past three years [3]. Shareholder Information - As of November 10, 2025, the number of shareholders for Yisheng Pharmaceutical was 19,700, a decrease of 1.92% from the previous period. The average number of circulating shares per person increased by 1.96% to 11,740 shares [2]. - Notably, as of September 30, 2025, the eighth largest circulating shareholder is the Nuoan Multi-Strategy Mixed A fund, which holds 1.9863 million shares as a new shareholder [3]. Stock Performance - As of November 19, Yisheng Pharmaceutical's stock price was 8.31 yuan per share, with a market capitalization of 2.75 billion yuan. The stock saw a trading volume of 12.1 million yuan and a turnover rate of 0.62% [1].

Group 1 - The core viewpoint of the news is that Wanbangde's stock has experienced significant fluctuations, with a year-to-date increase of 107.62% but a recent decline of 9.25% over the last five trading days [1] - As of November 19, Wanbangde's stock price was reported at 13.35 yuan per share, with a total market capitalization of 8.166 billion yuan [1] - The company has seen a net inflow of main funds amounting to 503,000 yuan, with large orders showing a mixed buying and selling trend [1] Group 2 - Wanbangde Medical Holdings Group Co., Ltd. was established on March 31, 1999, and listed on November 20, 2006, with its main business involving the production and sales of aluminum processing products and medical devices [2] - The revenue composition of Wanbangde includes 41.63% from medical devices, 24.69% from chemical raw materials and preparations, 19.61% from other goods, and 14.07% from traditional Chinese medicine [2] - As of September 30, the number of shareholders decreased by 32.75% to 26,400, while the average circulating shares per person increased by 48.70% to 20,944 shares [2] Group 3 - Wanbangde has distributed a total of 613 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [3]

Core Viewpoint - Lu Kang Pharmaceutical's stock has experienced fluctuations, with a recent decline of 2.02% and a year-to-date increase of 7.76%, indicating volatility in its market performance [1][2]. Financial Performance - For the period from January to September 2025, Lu Kang Pharmaceutical reported a revenue of 4.624 billion yuan, a year-on-year decrease of 0.91%, and a net profit attributable to shareholders of 141 million yuan, down 59.32% year-on-year [2]. - The company has cumulatively distributed 693 million yuan in dividends since its A-share listing, with 248 million yuan distributed over the last three years [3]. Stock Market Activity - As of November 19, Lu Kang Pharmaceutical's stock price was 10.17 yuan per share, with a total market capitalization of 9.139 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" seven times this year, with the most recent appearance on April 2, where it recorded a net buy of -648.76 million yuan [1]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 8.54% to 113,500, while the average number of tradable shares per person increased by 9.33% to 7,915 shares [2]. - Among the top ten circulating shareholders, the Southern CSI 1000 ETF held 6.5781 million shares, a decrease of 84,600 shares compared to the previous period [3].

Core Viewpoint - Guizhou BaiLing's stock price has experienced a decline recently, despite a significant increase of 52.73% year-to-date, indicating potential volatility in the market [2]. Group 1: Stock Performance - As of November 18, Guizhou BaiLing's stock price was 5.88 CNY per share, with a market capitalization of 8.218 billion CNY [1]. - The stock has seen a decline of 2.16% in the last five trading days, 2.00% in the last 20 days, and 2.97% in the last 60 days [2]. - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent instance on August 5, where it recorded a net buy of -23.773 million CNY [2]. Group 2: Financial Performance - For the period from January to September 2025, Guizhou BaiLing reported revenue of 2.102 billion CNY, a year-on-year decrease of 24.28%, and a net profit attributable to shareholders of 56.8144 million CNY, down 35.60% year-on-year [2]. - The company has not distributed any dividends in the last three years, with a total payout of 1.447 billion CNY since its A-share listing [3]. Group 3: Shareholder Information - As of November 10, the number of shareholders for Guizhou BaiLing was 85,800, a decrease of 10.86% from the previous period, with an average of 14,132 circulating shares per person, an increase of 12.19% [2]. - Hong Kong Central Clearing Limited is the fourth-largest circulating shareholder, holding 14.0733 million shares as a new investor [3].

Core Viewpoint - Harbin Pharmaceutical Group Co., Ltd. (哈药股份) has experienced a decline in stock price and financial performance, with significant net outflows of capital and a decrease in both revenue and net profit year-on-year [1][2][3] Financial Performance - As of September 30, 2025, Harbin Pharmaceutical reported a revenue of 12.02 billion yuan, a year-on-year decrease of 1.92% [2] - The net profit attributable to shareholders was 329 million yuan, reflecting a significant year-on-year decline of 35.35% [2] - The company's stock price has dropped by 9.20% year-to-date, with a recent trading price of 3.75 yuan per share [1] Stock Market Activity - On November 18, 2025, the stock price fell by 2.09%, with a trading volume of 116 million yuan and a turnover rate of 1.21% [1] - The company has seen a net outflow of 14.28 million yuan in principal funds, with large orders showing a buy of 24.06 million yuan and a sell of 29.60 million yuan [1] - Harbin Pharmaceutical has appeared on the stock market's "龙虎榜" three times this year, with the latest occurrence on January 13 [1] Shareholder Information - As of September 30, 2025, the number of shareholders increased to 98,100, with an average of 25,665 circulating shares per person, a decrease of 1.08% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which reduced its holdings by 18.56 million shares [3] Dividend History - Since its A-share listing, Harbin Pharmaceutical has distributed a total of 7.3 billion yuan in dividends, but there have been no dividends paid in the last three years [3]

以岭药业所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：抗流感、医药电商、禽流感 药物、幽门螺杆概念、中药等。 截至9月30日，以岭药业股东户数15.27万，较上期减少10.22%；人均流通股9013股，较上期增加 11.38%。2025年1月-9月，以岭药业实现营业收入58.68亿元，同比减少7.82%；归母净利润10.00亿元， 同比增长80.33%。 分红方面，以岭药业A股上市后累计派现44.55亿元。近三年，累计派现18.38亿元。 11月18日，以岭药业盘中下跌2.01%，截至09:58，报19.51元/股，成交3.47亿元，换手率1.28%，总市值 325.95亿元。 资金流向方面，主力资金净流出3907.66万元，特大单买入966.15万元，占比2.79%，卖出2662.36万元， 占比7.68%；大单买入6332.97万元，占比18.27%，卖出8544.41万元，占比24.65%。 以岭药业今年以来股价涨24.19%，近5个交易日跌4.69%，近20日涨13.89%，近60日涨23.25%。 今年以来以岭药业已经1次登上龙虎榜，最近一次登上龙虎榜为1月6日，当日龙虎榜净买入640 ...

Core Viewpoint - The company, Jiuzhoutong, has experienced fluctuations in its stock price and trading volume, with a recent decline of 2.11% as of November 17, 2023, while its year-to-date stock price has increased by 3.62% [1] Group 1: Stock Performance - As of November 17, 2023, Jiuzhoutong's stock price is 5.10 CNY per share, with a total market capitalization of 25.717 billion CNY [1] - The stock has seen a trading volume of 91.7747 million CNY, with a turnover rate of 0.35% [1] - Year-to-date, the stock price has increased by 3.62%, but it has decreased by 1.35% over the last five trading days and by 4.49% over the last 60 days [1] Group 2: Financial Performance - For the period from January to September 2025, Jiuzhoutong reported a revenue of 119.327 billion CNY, reflecting a year-on-year growth of 5.20% [2] - The net profit attributable to shareholders for the same period was 1.975 billion CNY, representing a year-on-year increase of 16.46% [2] Group 3: Shareholder Information - As of September 30, 2025, the number of Jiuzhoutong's shareholders has increased by 36.47% to 57,000 [2] - The average number of circulating shares per shareholder is 88,537, which has decreased by 26.72% compared to the previous period [2] - The company has distributed a total of 5.267 billion CNY in dividends since its A-share listing, with 2.911 billion CNY distributed in the last three years [3]

神奇制药今年以来股价涨2.98%，近5个交易日涨3.91%，近20日涨9.68%，近60日涨0.58%。 资料显示，上海神奇制药投资管理股份有限公司位于上海市威海路128号长发大厦613室，成立日期1992 年7月22日，上市日期1992年8月20日，公司主营业务涉及药品的研发、生产与销售。主营业务收入构成 为：其他特色产品系列45.33%，抗肿瘤药系列27.73%，中药经典止咳系列8.54%，三高慢病产品系列 5.51%，皮肤外用抗菌系列4.81%，苗药强筋健骨系列4.62%，经典滋补产品系列2.61%，神奇娃娃儿药 系列0.84%。 神奇制药所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：零售药店、医药电商、 抗流感、小盘、中药等。 11月17日，神奇制药（维权）盘中下跌2.12%，截至09:54，报6.91元/股，成交4115.37万元，换手率 1.23%，总市值36.90亿元。 资金流向方面，主力资金净流出781.00万元，特大单买入191.68万元，占比4.66%，卖出444.69万元，占 比10.81%；大单买入455.12万元，占比11.06%，卖出983.11万元，占比23.8 ...